allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.
Company profile
Ticker
ALLK
Exchange
Website
CEO
Robert Alexander
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ALLK stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
23 Apr 24
8-K
Departure of Directors or Certain Officers
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
26 Feb 24
8-K
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
12 Feb 24
8-K
Regulation FD Disclosure
2 Feb 24
8-K
Regulation FD Disclosure
16 Jan 24
8-K
Allakos Announces a Restructuring to Focus on Development of AK006
16 Jan 24
Latest ownership filings
144
Notice of proposed sale of securities
19 Mar 24
4
Harlan Baird Radford
7 Mar 24
4
Adam Tomasi
6 Mar 24
4
Robert Alexander
6 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Harlan Baird Radford
21 Feb 24
4
Chin Hyok Lee
21 Feb 24
4
Robert Alexander
21 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 71.99 mm | 71.99 mm | 71.99 mm | 71.99 mm | 71.99 mm | 71.99 mm |
Cash burn (monthly) | (no burn) | 11.23 mm | 16.07 mm | 14.77 mm | 9.83 mm | 11.58 mm |
Cash used (since last report) | n/a | 77.38 mm | 110.73 mm | 101.80 mm | 67.71 mm | 79.81 mm |
Cash remaining | n/a | -5.39 mm | -38.73 mm | -29.80 mm | 4.29 mm | -7.82 mm |
Runway (months of cash) | n/a | -0.5 | -2.4 | -2.0 | 0.4 | -0.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 134 |
Opened positions | 31 |
Closed positions | 29 |
Increased positions | 40 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 302.03 bn |
Total shares | 93.12 mm |
Total puts | 100.00 |
Total calls | 28.00 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
BVF | 8.65 mm | $37.72 bn |
Alta Partners VIII | 6.45 mm | $862.56 mm |
NEA Management | 6.15 mm | $26.80 bn |
New Enterprise Associates 16 | 6.15 mm | $34.06 mm |
BLK Blackrock | 5.98 mm | $26.07 bn |
Logos Global Management | 5.25 mm | $22.89 bn |
Biotechnology Value Fund L P | 5.01 mm | $29.24 mm |
RiverVest Venture Management | 4.89 mm | $21.31 bn |
STT State Street | 4.38 mm | $19.08 bn |
T. Rowe Price | 3.85 mm | $16.83 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Harlan Baird Radford | Common Stock | Payment of exercise | Dispose F | No | No | 1.35 | 32,142 | 43.39 k | 306,019 |
5 Mar 24 | Adam Tomasi | Common Stock | Payment of exercise | Dispose F | No | No | 1.44 | 47,392 | 68.24 k | 597,473 |
4 Mar 24 | Robert Alexander | Common Stock | Payment of exercise | Dispose F | No | No | 1.48 | 70,910 | 104.95 k | 873,776 |
Press releases
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
26 Feb 24
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
12 Feb 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
11 Feb 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
7 Feb 24